Here are relevant reports on : minimal-residual-disease-mrd-market
-
Bioabsorbable Stents Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022
The global bioresorbable stents market is projected to reach USD 417.2 Million by 2022, at a CAGR of 11.5%. Market growth of bioresorbable stents is attributed to the growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and patients’ preference for minimally invasive therapies. However, factors such as the increasing product withdrawals due to severe complications of these stents may hamper market growth. The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
- Published: August 2017
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) & Region - Global Forecast to 2028
The global tissue diagnostics market, valued at US$5.2 billion in 2022, stood at US$5.6 billion in 2023 and is projected to advance at a resilient CAGR of 8.4% from 2023 to 2028, culminating in a forecasted valuation of US$8.4 billion by the end of the period. The new research study consists of an industry trend analysis of the market. Market growth is driven by the growing private diagnostic centers globally, and rising geriatric population with subsequent growth in chronic and infectious diseases.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
- Published: October 2017
- Price: $ 4950
- TOC Available:
-
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
Global respiratory diagnostics market valued at $5.84B in 2024, reached $6.17B in 2025, and is projected to grow at a robust 6.5% CAGR, hitting $9.02B by 2030. The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population and the rise in sedentary lifestyles, growing awareness about respiratory health, and advancements in diagnostic technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market, valued at US$12.3 billion in 2023, stood at US$13.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$21.2 billion by the end of the period. Growth in the market is primarily driven by the technological improvements in the DNA diagnostics industry and the growing need for personalized treatment and early disease diagnosis in developing nations. Also, the increased investments by healthcare-based companies are majorly contributing to growth of the market.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024
The electronic drug delivery system market is expected to grow from USD 7.8 billion in 2019 to USD 11.9 billion by 2024, at a compound annual growth rate (CAGR) of 8.7%. during the forecast period.The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029
The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031
The global autoimmunity diagnostics market, valued at US$5.26 billion in 2024, stood at US$5.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2031, culminating in a forecasted valuation of US$8.98 billion by the end of the period. The autoimmunity diagnostics market is consistently growing, fueled by several key factors. These include the rising prevalence of autoimmune disease, growing awareness about early and accurate diagnosis, increasing research activities, and rapid advancements in diagnostic technologies.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Middle East & Africa In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Infectious Disease) - Forecast to 2031
The Middle East & Africa in vitro diagnostics market is valued at an estimated USD 3.49 billion in 2026 and is projected to reach USD 4.42 billion by 2031, at a CAGR of 4.8% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Becton, Dickinson and Company (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), and QuidelOrtho Corporation (US).
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
